

## **Product Specification Sheet**

LY2484595 (Evacetrapib) **Product Name:** 

**Catalog Number:** C5248

**Technical information:** 

 $C_{31}H_{36}F_6N_6O_2$ Chemical Formula:

> CAS #: 1186486-62-3

Molecular Weight: 638.65

> Purity: > 98%

Appearance: White Crystalline solid

Solubility: Soluble in DMSO up to 22 mM

Chemical Name: Trans-4-{{(5S)-5-[{[3,5-bis(trifluoromethyl)phenyl]methyl}(2-methyl-2H-tetrazol-5-yl)amino]-7,9-

dimethyl-2,3,4,5-tetrahydro-1H-benzazepin-1-yl}methyl) cyclohexanecarboxylic acid

LY2484595

(Evacetrapib)

Storage: Store solid powder at 4°C desiccated; Store DMSO solution at -20°C.

Shelf Life: In the unopened package, powder is stable for 1 year and DMSO solution is stable for 6 months

under proper storage condition.

Handling: • To make 10 mM stock solution, add 0.157mL of DMSO for each mg of LY2484595 (Evacetrapib)

• For DMSO solution, briefly spin the vial at 500 rpm in a 50 mL conical tube to ensure maximum sample recovery.

**Biological Activity:** 

LY-2484595 (Evacetrapib) is a benzazepine-based, selective inhibitor of cholesteryl ester transfer protein (CETP) at an IC50 value of 5.5 nM for human recombinant CETP. Inhibition in human plasma was 3.6 nM IC50. [1] In H295R cells at concentrations up to 10 uM, LY-2484595 has been shown to elevate HDL cholesterol without inducing aldosterone, cortisol synthesis, or increasing blood pressure.

In a randomized controlled trial of 398 patients with elevated LDL and low HDL, LY-2484595 was shown to be effective in lowering LDL and raising HDL. In combination with statins, LY-2484595 showed greater efficacy in lowering LDL with no adverse effects. [2]

- Reference: 1. Cao et al., Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure. J. Lipid Res. 2011, 52, 2169-2176. Pubmed ID: 21957197
  - 2. Nicholls et al., Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 2011, 306(19), 2099-2109. Pubmed ID: 22089718

To reorder: http://www.cellagentech.com/LY2484595-Evacetrapib/

For Technical Support: technical@cellagentech.com

Chemicals are sold for research use only, not for clinical or diagnostic use.